IT1398361B1 - Uso di mutanti dominanti negativi di sam68 per il trattamento della sma - Google Patents

Uso di mutanti dominanti negativi di sam68 per il trattamento della sma

Info

Publication number
IT1398361B1
IT1398361B1 ITRM2009A000021A ITRM20090021A IT1398361B1 IT 1398361 B1 IT1398361 B1 IT 1398361B1 IT RM2009A000021 A ITRM2009A000021 A IT RM2009A000021A IT RM20090021 A ITRM20090021 A IT RM20090021A IT 1398361 B1 IT1398361 B1 IT 1398361B1
Authority
IT
Italy
Prior art keywords
sam68
negative dominant
dominant mutants
sma treatment
sma
Prior art date
Application number
ITRM2009A000021A
Other languages
English (en)
Inventor
Maria Paola Paronetto
Simona Pedrotti
Original Assignee
Fond Santa Lucia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fond Santa Lucia filed Critical Fond Santa Lucia
Priority to ITRM2009A000021A priority Critical patent/IT1398361B1/it
Priority to US13/145,629 priority patent/US20120071415A1/en
Priority to EP10700751A priority patent/EP2384202A1/en
Priority to PCT/EP2010/050650 priority patent/WO2010084136A1/en
Publication of ITRM20090021A1 publication Critical patent/ITRM20090021A1/it
Application granted granted Critical
Publication of IT1398361B1 publication Critical patent/IT1398361B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ITRM2009A000021A 2009-01-21 2009-01-21 Uso di mutanti dominanti negativi di sam68 per il trattamento della sma IT1398361B1 (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ITRM2009A000021A IT1398361B1 (it) 2009-01-21 2009-01-21 Uso di mutanti dominanti negativi di sam68 per il trattamento della sma
US13/145,629 US20120071415A1 (en) 2009-01-21 2010-01-20 Dominant negative mutants of sam68 for use in the treatment of spinal muscular atrophy (sma)
EP10700751A EP2384202A1 (en) 2009-01-21 2010-01-20 A dominant negative mutants of sam68 for use in the treatment of spinal muscular atrophy (sma)
PCT/EP2010/050650 WO2010084136A1 (en) 2009-01-21 2010-01-20 A dominant negative mutants of sam68 for use in the treatment of spinal muscular atrophy (sma)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2009A000021A IT1398361B1 (it) 2009-01-21 2009-01-21 Uso di mutanti dominanti negativi di sam68 per il trattamento della sma

Publications (2)

Publication Number Publication Date
ITRM20090021A1 ITRM20090021A1 (it) 2010-07-22
IT1398361B1 true IT1398361B1 (it) 2013-02-22

Family

ID=40974561

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM2009A000021A IT1398361B1 (it) 2009-01-21 2009-01-21 Uso di mutanti dominanti negativi di sam68 per il trattamento della sma

Country Status (4)

Country Link
US (1) US20120071415A1 (it)
EP (1) EP2384202A1 (it)
IT (1) IT1398361B1 (it)
WO (1) WO2010084136A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012138487A2 (en) * 2011-04-07 2012-10-11 The Board Of Regents Of The University Of Texas System Oligonucleotide modulation of splicing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1133993A1 (en) * 2000-03-10 2001-09-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Substances for the treatment of spinal muscular atrophy
US7838657B2 (en) * 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
PL2548560T3 (pl) * 2005-06-23 2015-11-30 Biogen Ma Inc Kompozycje i sposoby modulowania splicingu SMN2

Also Published As

Publication number Publication date
EP2384202A1 (en) 2011-11-09
WO2010084136A1 (en) 2010-07-29
US20120071415A1 (en) 2012-03-22
ITRM20090021A1 (it) 2010-07-22

Similar Documents

Publication Publication Date Title
SMT201400008B (it) Uso di betanecolo per il trattamento di xerostomia
BRPI0917535A2 (pt) uso de insulina de ação ultra rápida
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
DK2477592T3 (da) Rollatorkørestol
CO6950473A2 (es) Novedosos derivados de purina y su uso en el tratamiento de enfermedades
BR112014009949A8 (pt) métodos de tratamento de hipersecreção de muco e uso de agentes
SMT201500057B (it) Uso della biotina per il trattamento della sclerosi multipla
SMT201500264B (it) Mutanti della frataxina
BRPI1005670A2 (pt) composições adjuvantes e métodos de uso
GB0919097D0 (en) Treatment of hard surfaces
BRPI1001277A2 (pt) uso de polioximetileno di (alquil poliglicol) éteres
IT1396692B1 (it) Struttura di protesi per amputati agli arti inferiori.
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
ITMI20080898A1 (it) Uso di batteri probiotici per il trattamento della iperomocisteinemia
BR112013008872A2 (pt) mecanismo de ajuste de dose e método de uso do mesmo
SMT201500086B (it) Uso del nifuratel per il trattamento di infezioni causate dalla specie atopobium
EP2475389A4 (en) USE OF AN ANTIBODY AGAINST IL6 FOR HEPCIDINE DEDUCTION IN CANCER PATIENTS
BRPI0909840A2 (pt) Uso de 4-tio-2-deoxinucleosídios
IT1395596B1 (it) Procedimento per la preparazione di sitagliptin
BR112013008617A2 (pt) mecanismo de ajuste de dose e método de uso do mesmo
IT1392635B1 (it) Trattamento ematico di ozonoterapia
SMT201600301B (it) USO TERAPEUTICO DELLA PROTEINAß2- MICROGLOBULINA
EP2503891A4 (en) PYRIMIDINE ETHER DERIVATIVES AND METHOD OF USE THEREOF
IT1398361B1 (it) Uso di mutanti dominanti negativi di sam68 per il trattamento della sma